Abstract:Despite significant advancements in immune checkpoint blockade (ICB) therapy, only few patients respond to the treatment. Non-immunogenic cold tumors lack T-cell infiltration, which results in reduced ICB therapeutic efficiency. Immune adjuvants can reprogram the non-immunogenic cold tumor microenvironment (TME) to inflamed hot TME by activating antigen presenting cells and improving T-cell homing. Here, we investigate the potentials of 558 (a novel TLR 7/8 agonist) and ADU-S100 (stimulator of interferon gene (STING) agonist in clinical trials) combination on improving the activity of ICB. Human TLR-specific reporter cell assay using HEK-BlueTM-hTLR7 and 8, confirmed the activation of both TLR 7 and TLR 8 with EC50 of 0.18 μM and 5.34 μM respectively, when treated with 558. In addition, treatment of human PBMCs with 558 increased the IFN-γ and TNF-α cytokine secretions. Moreover, the levels of IL-10, an anti-inflammatory cytokine were not increased upon treatment with 558. Although treatment of bone marrow derived dendritic cells (BMDC) with 558 resulted in CD40 expression, a reduced expression of CD80 and CD86, costimulatory molecules that are required for T-cell activation, was observed. Interestingly, 558 in combination with ADU-S100 not only increased the CD40 expression but also improved the expression of CD80 (4-fold) and CD86 on BMDCs. Furthermore, the levels of pro-inflammatory cytokines TNF-α and IL-6 was significantly increased when BMDCs were treated with 558 and ADU-S100 combination compared to the individual treatments. TME constitute M2 polarized macrophages that promote secretion of anti-inflammatory cytokines and favor tumor progression. Interestingly, 558 and ADU-S100 combination reduced the expression of CD206, a mannose receptor that is highly expressed on M2 macrophages and improved the expression of CD80 (25-fold) and CD86 (6-fold) compared to 558 treatments alone. These results confirmed the polarization of M2 macrophages to immunogenic M1 macrophages. Overall, these studies indicate promising potential of 558 and ADU-S100 combination in reprogramming the TME to aid in effective cancer treatments. Citation Format: Vishnu Revuri, Shubhmita Bhatnagar, John Schultz, Peter Larson, David M. Ferguson, Jayanth Panyam. STING and TLR 7/8 Agonist combination can improve immune checkpoint blockade therapy efficiency [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5587.

Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy

Targeting STING signaling for the optimal cancer immunotherapy

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models

Abstract 5587: STING and TLR 7/8 Agonist combination can improve immune checkpoint blockade therapy efficiency

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

Tumor Microenvironment‐Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy

STING Activation in Cancer Immunotherapy

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity

Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway

Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

Improvement Strategy for Immune Checkpoint Blockade: A Focus on the Combination with Immunogenic Cell Death Inducers.

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade